BSE filing, NSE: EMCURE. Summary written from the filing by ALFA Finder's alert engine.
Emcure Pharmaceuticals Ltd: key numbers
- Share price
- ₹1,875.00
- Market cap
- ₹35,571 Cr
- Revenue (annual)
- ₹9,204 Cr
- Net profit (annual)
- ₹924.4 Cr
- P/E (TTM)
- 35.2×Sector 46.1×
- Promoter holding
- 77.82%-0.01% QoQ
- FII holding
- 4.94%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Emcure Pharmaceuticals Ltd
All →Emcure Pharmaceuticals Board Meeting Date
Emcure Pharmaceuticals will hold a board meeting on November 03, 2026, to consider and approve the company's standalone and consolidated financial results for the quarter.
Emcure Pharmaceuticals Acquisition
Emcure Pharmaceuticals approved the merger of its wholly-owned subsidiaries, Zuventus Healthcare and Emcutix Biopharmaceuticals, into itself. The internal restructuring involves no cash consideration or share issuance.
Emcure Pharmaceuticals Legal & Regulatory
Emcure Pharmaceuticals received Income-tax Department orders imposing aggregate penalties of Rs. 57.74 Crore for assessment years 2015-16 to 2021-22. The company is evaluating legal remedies.
- Value
- ₹57.74 Cr
Emcure Pharmaceuticals Investor Presentation: Key Takeaways
Emcure reported strong Q1 FY27 momentum with revenue of INR 92,035 Mn and PAT of INR 9,413 Mn for FY26. Strategy focuses on chronic-led domestic expansion and differentiated international portfolios.
Emcure Pharmaceuticals Annual General Meeting
Emcure Pharmaceuticals held its 45th Annual General Meeting on September 21, 2026. The meeting transacted ordinary and special business, including the approval of a final dividend.
Emcure Pharmaceuticals Employee Stock Options
Emcure Pharmaceuticals allotted 11,400 equity shares to employees following the exercise of vested options under the ESOP scheme. This increases the company's total issued share capital.
Other other announcement announcements
All →Mahindra & Mahindra Financial Services Other Announcement
Mahindra & Mahindra Financial filed its ALM statement as of September 30, 2026, submitted to RBI. It is a periodic regulatory return with no new transaction.
ACME Solar Holdings Other Announcement
ACME Solar filed the CARE Ratings monitoring agency report on its Rs.2,800 crore QIP for the quarter ended 30 September 2026. The report shows no deviation from the offer objects.
eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.